Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (94736)	10/25/2001 11:44:55 AM
From: bigbuk	Respond to of 150070

HYRB gonna be a good one i in and adding

To: SSP who wrote (94736)	10/26/2001 8:57:19 PM
From: Jim Bishop	Respond to of 150070

HYBR LIST stock had some news today: HyperBaric Announces Listing On Frankfurt Stock Exchange PALO ALTO, Calif.--(BUSINESS WIRE)--Oct. 26, 2001--HyperBaric Systems (OTCBB:HYRB - news) filed its application for listing on the Frankfurt Stock Exchange in Germany to introduce the company to the European Market. Harry Masuda, HyperBaric Systems president, said the company has met the admission requirements and has been accepted for listing on the Frankfurt Stock Exchange, specializing in emerging Small Caps. Trading of the stock in Frankfurt commenced Oct. 26, 2001 with the German security number (WKN) 806614 and the ticker symbol ``HYT.'' Henry Bohl, CEO of Baltic Investment Group, a prominent German consulting company specializing in listings and IR/PR in Europe, personally handled the transaction. ``European investors are trading American and Canadian stocks more and more often in continually larger amounts. With the listing in Germany, HyperBaric Systems is presenting an exciting opportunity to all European investors, both institutional and retail, and opening a great new market for the company,'' Masuda said. HyperBaric Systems and Baltic Investment Group will carry out an extensive Investor Road show throughout Europe starting in November. ``We have received numerous inquiries from interested European individuals and investment groups,'' Masuda said. ``We believe Europe is an extremely important market for HyperBaric Systems with enormous potential.'' HyperBaric Systems has headquarters in Palo Alto, with research facilities in Russia and Michigan. The company is primarily focused on the preservation-extension and safety of platelets, the congealing component of blood. Disclaimer Information contained in this news release other than historical information should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Winners Internet Network Inc. involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release. Accordingly, actual results may differ materially from those in any forward-looking statements. --------------------------------------------------------------------------------

To: SSP who wrote (94736)	10/26/2001 8:58:37 PM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

ACAM on the LIST, I believe this article when talking about the close, means Thursday, I show close at $40 Friday. Acambis continues climb on germ war fears LONDON, Oct 26 (Reuters) - Shares in Britain's Acambis Plc, which is developing a new vaccine for smallpox, rose 14 percent in early Friday trading after its American Depositary Receipts climbed a similar amount in New York on fears of germ warfare. At 0835 GMT, the shares were 31-1/2 pence higher at 261p, valuing Acambis at around 238 million pounds ($340 million). ``It's the same story as before. The ADRs shoot up on the anthrax scare and the shares in London follow,'' said one trader. In New York, Acambis' American Depositary Receipts (NasdaqNM:ACAM - news) closed up 14 percent at $38.36. Acambis's shares have more than doubled since the September 11 attacks on the United States which, along with a spate of anthrax attacks, have fuelled fears about germ warfare. Acambis said earlier this month that it had speeded up development of a new smallpox vaccine. The company has a 20-year contract with the U.S. Centers for Disease Control and Prevention to supply an initial 40 million doses of the vaccine. Acambis had said it would begin clinical trials early next year and make the first deliveries in 2004. It has not disclosed the details of its new timetable.